SCHEMBL3485485

SCHEMBL3485485

O=S(=O)(c1cccc(Cl)c1)N(C1CCNCC1)C1CC1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 3/20 0.50
HTR2A P28223 1/20 0.50
HTR6 P50406 9/20 0.46
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
KMT2A Q03164 1/20 0.43
HTR1A P08908 2/20 0.42
HTR1D P28221 2/20 0.42
HTR1B P28222 2/20 0.42
HTR7 P34969 2/20 0.42
HTR2B P41595 2/20 0.42
SLC6A2 P23975 2/20 0.40
SLC6A4 P31645 2/20 0.40
CYP3A4 P08684 2/20 0.40
CHRM1 P11229 2/20 0.40
KCNA5 P22460 1/20 0.39
CHRM3 P20309 1/20 0.39
SLC6A3 Q01959 1/20 0.39
KCNH2 Q12809 1/20 0.39
MMP2 P08253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13543315 0.84 HTR2A (0.70) HTR2CHTR2AHTR6MEN1ALDH1A1
SCHEMBL3486045 0.83 HTR2C (0.51) HTR2CHTR2AHTR6KMT2AHTR1D
SCHEMBL3485433 0.83 HTR2C (0.50) HTR2CHTR2AHTR6HTR2BSLC6A2
SCHEMBL231306 0.82 HTR2A (0.46) HTR2CHTR2AHTR6ALDH1A1SLC6A2
SCHEMBL532533 0.82 KDM4E (0.46) HTR2CHTR2AHTR6MEN1ALDH1A1
SCHEMBL3485825 0.81 CACNA1B (0.55) HTR2CCYP3A4
SCHEMBL4278784 0.77 CACNA1B (0.45) HTR6SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL3226090 0.76 HTR6 (0.50) HTR2CHTR2AHTR6MEN1ALDH1A1
SCHEMBL3561054 0.73 HTR2C (0.46) HTR2CHTR2AHTR6MEN1ALDH1A1
SCHEMBL13541682 0.71 SLC6A2 (0.56) HTR6SLC6A2SLC6A4CYP3A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791264-B2 Benzenesulfonamide compounds and their use as blockers of calcium channels PURDUE PHARMA L.P. (US) 2014-07-29 US disclosed
US-8791264-B2 Benzenesulfonamide compounds and their use as blockers of calcium channels PURDUE PHARMA L.P. (US) 2014-07-29 US disclosed
US-20100022595-A1 Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels PURDUE PHARMA L.P. (CT) 2010-01-28 US disclosed
US-20100022595-A1 Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels PURDUE PHARMA L.P. (CT) 2010-01-28 US disclosed
WO-2007118853-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS EURO-CELTIQUE S.A. (LU) 2007-10-25 WO disclosed
WO-2007118853-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS EURO-CELTIQUE S.A. (LU) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022595-A1 Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels CACNA1A, CACNA1E, CACNA1B HTR2C 431/4885HTR2A 499/4885HTR6 391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.